TrakCel

Executive Summary

TrakCel is a UK-based software company specializing in supply chain orchestration for cell and gene therapies. Its flagship platform, OCELLOS, built on Salesforce, provides modular solutions for tracking therapies from patient enrollment to final treatment, ensuring regulatory compliance, full audit trails, and real-time visibility. Founded in 2012, the company addresses critical logistics challenges in the rapidly growing advanced therapy market, where cold chain management and traceability are paramount. As cell and gene therapies gain regulatory approvals and commercial adoption accelerates, TrakCel's platform plays a key role in enabling scalable and compliant distribution. The company is well-positioned to benefit from the expanding pipeline of personalized medicines, with its technology increasingly recognized as essential infrastructure for therapy manufacturers, contract development and manufacturing organizations (CDMOs), and healthcare providers. Despite being privately held and lacking disclosed financials, TrakCel's niche focus and integration with Salesforce provide a competitive moat. The company's growth trajectory depends on its ability to secure partnerships with major biopharma players and adapt to evolving regulatory standards across regions. With the advanced therapy market projected to grow substantially over the next decade, TrakCel's platform is strategically aligned to capture value from the complex supply chain requirements of these life-saving therapies.

Upcoming Catalysts (preview)

• Q3 2026Major Partnership with Top 10 Biopharma for Cell Therapy Supply Chain70% success
• Q4 2026Launch of Enhanced OCELLOS Module for Autologous Therapy Tracking85% success
• Q1 2027Regulatory Certification (e.g., FDA 21 CFR Part 11) for Expanded US Market60% success